Comprehensive Stock Comparison
Compare Ainos, Inc. (AIMD) vs Vertex Pharmaceuticals Incorporated (VRTX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  VRTX | 8.9% revenue growth vs AIMD's -83.0% |
| Quality / Margins | VRTX | 31.3% net margin vs AIMD's -132.3% |
| Stability / Safety | VRTX | Beta 0.44 vs AIMD's 1.19, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | VRTX | -2.8% vs AIMD's -38.6% |
| Efficiency (ROA) | VRTX | 14.8% ROA vs AIMD's -65.9%, ROIC 22.8% vs -39.8% |
Who Each Stock Is For
Income & stability
VRTXbeta 0.44
Growth exposure
VRTXRev growth 8.9%, EPS growth 8.4%, 3Y rev CAGR 10.4%
Long-term compounding (10Y)
VRTX425.4% 10Y total return vs AIMD's -97.4%
Sleep-well-at-night portfolio
VRTXLower volatility, beta 0.44, Low D/E 19.8%, current ratio 2.90x
Defensive / Recession hedge
VRTXBeta 0.44, current ratio 2.90x
Business Model
What each company does and how it makes money
Ainos is a healthcare technology company developing point-of-care diagnostic tests and novel medical treatments. It generates revenue primarily from COVID-19 testing kits and related cloud-based management software — with additional income from its low-dose oral interferon alpha formulation and synthetic RNA platform. The company's competitive advantage lies in its integrated approach combining physical test kits with digital cloud-based management systems for healthcare providers.
Vertex Pharmaceuticals is a biotechnology company focused on developing and commercializing transformative medicines for serious diseases, with its flagship franchise targeting cystic fibrosis. It generates nearly all its revenue from CF therapies — primarily Trikafta/Kaftrio — while building a pipeline in pain, kidney disease, and type 1 diabetes. Its moat stems from deep scientific expertise in CFTR biology and a dominant, near-monopoly position in the CF treatment market.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
VRTX 4
AIMD 1VRTX5/5 metricsAIMD2/3 metricsVRTX7/9 metricsVRTX6/6 metricsVRTX2/2 metricsVRTX leads in 4 of 6 categories (Financial Metrics, Profitability & Efficiency). AIMD leads in 1 (Valuation Metrics).
Financial Metrics (TTM)
VRTX is the larger business by revenue, generating $11.7B annually — 103712.1x AIMD's $113,037. VRTX is the more profitable business, keeping 31.3% of every revenue dollar as net income compared to AIMD's -132.3%.
| Metric | AIMDAinos, Inc. | VRTXVertex Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $113,037 | $11.7B |
| EBITDAEarnings before interest/tax | -$10M | $4.2B |
| Net IncomeAfter-tax profit | -$15M | $3.7B |
| Free Cash FlowCash after capex | -$5M | $3.3B |
| Gross MarginGross profit ÷ Revenue | +82.7% | +86.3% |
| Operating MarginEBIT ÷ Revenue | -126.7% | +34.1% |
| Net MarginNet income ÷ Revenue | -132.3% | +31.3% |
| FCF MarginFCF ÷ Revenue | -41.2% | +28.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +11.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -93.9% | +4.7% |
Valuation Metrics
| Metric | AIMDAinos, Inc. | VRTXVertex Pharmaceut… |
|---|---|---|
| Market CapShares × price | $7M | $121.4B |
| Enterprise ValueMkt cap + debt − cash | $15M | $120.0B |
| Trailing P/EPrice ÷ TTM EPS | -0.97x | 31.19x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 24.68x |
| PEG RatioP/E ÷ EPS growth rate | — | 3.77x |
| EV / EBITDAEnterprise value multiple | — | 25.60x |
| Price / SalesMarket cap ÷ Revenue | 349.20x | 10.11x |
| Price / BookPrice ÷ Book value/share | 0.92x | 6.61x |
| Price / FCFMarket cap ÷ FCF | — | 38.01x |
Profitability & Efficiency
VRTX delivers a 21.2% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $-149 for AIMD. VRTX carries lower financial leverage with a 0.20x debt-to-equity ratio, signaling a more conservative balance sheet compared to AIMD's 0.77x. On the Piotroski fundamental quality scale (0–9), VRTX scores 5/9 vs AIMD's 2/9, reflecting solid financial health.
| Metric | AIMDAinos, Inc. | VRTXVertex Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -148.9% | +21.2% |
| ROA (TTM)Return on assets | -65.9% | +14.8% |
| ROICReturn on invested capital | -39.8% | +22.8% |
| ROCEReturn on capital employed | -50.0% | +23.0% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 |
| Debt / EquityFinancial leverage | 0.77x | 0.20x |
| Net DebtTotal debt minus cash | $8M | $3.7B |
| Cash & Equiv.Liquid assets | $4M | $5.1B |
| Total DebtShort + long-term debt | $12M | $3.7B |
| Interest CoverageEBIT ÷ Interest expense | -19.79x | 348.55x |
Total Returns (with DRIP)
A $10,000 investment in VRTX five years ago would be worth $22,544 today (with dividends reinvested), compared to $75 for AIMD. Over the past 12 months, VRTX leads with a -2.8% total return vs AIMD's -38.6%. The 3-year compound annual growth rate (CAGR) favors VRTX at 17.9% vs AIMD's -55.0% — a key indicator of consistent wealth creation.
| Metric | AIMDAinos, Inc. | VRTXVertex Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | -13.7% | +5.7% |
| 1-Year ReturnPast 12 months | -38.6% | -2.8% |
| 3-Year ReturnCumulative with dividends | -90.9% | +63.9% |
| 5-Year ReturnCumulative with dividends | -99.3% | +125.4% |
| 10-Year ReturnCumulative with dividends | -97.4% | +425.4% |
| CAGR (3Y)Annualised 3-year return | -55.0% | +17.9% |
Risk & Volatility
VRTX is the less volatile stock with a 0.44 beta — it tends to amplify market swings less than AIMD's 1.19 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VRTX currently trades 92.0% from its 52-week high vs AIMD's 33.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AIMDAinos, Inc. | VRTXVertex Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.19x | 0.44x |
| 52-Week HighHighest price in past year | $4.50 | $519.68 |
| 52-Week LowLowest price in past year | $1.26 | $362.50 |
| % of 52W HighCurrent price vs 52-week peak | +33.6% | +92.0% |
| RSI (14)Momentum oscillator 0–100 | 42.8 | 50.0 |
| Avg Volume (50D)Average daily shares traded | 829K | 1.4M |
Analyst Outlook
| Metric | AIMDAinos, Inc. | VRTXVertex Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $545.08 |
| # AnalystsCovering analysts | — | 55 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.7% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Jan 21 | Mar 26 | Change |
|---|---|---|---|
| Ainos, Inc. (AIMD) | 100 | 2.75 | -97.2% |
| Vertex Pharmaceutic… (VRTX) | 100 | 209.7 | +109.7% |
Vertex Pharmaceutic… (VRTX) returned +125% over 5 years vs Ainos, Inc. (AIMD)'s -99%. A $10,000 investment in VRTX 5 years ago would be worth $22,544 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Ainos, Inc. (AIMD) | $0.00 | $20729.00 | — |
| Vertex Pharmaceutic… (VRTX) | $1.7B | $12.0B | +605.1% |
Vertex Pharmaceuticals Incorporated's revenue grew from $1.7B (2016) to $12.0B (2025) — a 24.2% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Ainos, Inc. (AIMD) | -2.5% | -717.0% | -29042.9% |
| Vertex Pharmaceutic… (VRTX) | -6.6% | 32.9% | +600.4% |
Vertex Pharmaceuticals Incorporated's net margin went from -7% (2016) to 33% (2025).
Chart 4P/E Ratio History — 8 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Vertex Pharmaceutic… (VRTX) | 144.1 | 29.6 | -79.5% |
Vertex Pharmaceuticals Incorporated has traded in a 21x–144x P/E range over 8 years; current trailing P/E is ~31x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Ainos, Inc. (AIMD) | -0.5 | -1.56 | -212.0% |
| Vertex Pharmaceutic… (VRTX) | -0.46 | 15.32 | +3430.4% |
Vertex Pharmaceuticals Incorporated's EPS grew from $-0.46 (2016) to $15.32 (2025).
Chart 6Free Cash Flow — 5 Years
Ainos, Inc. generated $-6M FCF in 2024 (-318% vs 2021). Vertex Pharmaceuticals Incorporated generated $3B FCF in 2025 (+33% vs 2021).
AIMD vs VRTX: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is AIMD or VRTX a better buy right now?
Vertex Pharmaceuticals Incorporated (VRTX) offers the better valuation at 31.2x trailing P/E (24.7x forward), making it the more compelling value choice. Analysts rate Vertex Pharmaceuticals Incorporated (VRTX) a "Buy" — based on 55 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AIMD or VRTX?
Over the past 5 years, Vertex Pharmaceuticals Incorporated (VRTX) delivered a total return of +125.4%, compared to -99.3% for Ainos, Inc. (AIMD). A $10,000 investment in VRTX five years ago would be worth approximately $23K today (assuming dividends reinvested). Over 10 years, the gap is even starker: VRTX returned +425.4% versus AIMD's -97.4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AIMD or VRTX?
By beta (market sensitivity over 5 years), Vertex Pharmaceuticals Incorporated (VRTX) is the lower-risk stock at 0.44β versus Ainos, Inc.'s 1.19β — meaning AIMD is approximately 169% more volatile than VRTX relative to the S&P 500. On balance sheet safety, Vertex Pharmaceuticals Incorporated (VRTX) carries a lower debt/equity ratio of 20% versus 77% for Ainos, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — AIMD or VRTX?
Vertex Pharmaceuticals Incorporated (VRTX) is the more profitable company, earning 32.9% net margin versus -717.0% for Ainos, Inc. — meaning it keeps 32.9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VRTX leads at 39.1% versus -667.7% for AIMD. At the gross margin level — before operating expenses — VRTX leads at 86.2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — AIMD or VRTX?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is AIMD or VRTX better for a retirement portfolio?
For long-horizon retirement investors, Vertex Pharmaceuticals Incorporated (VRTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.44), +425.4% 10Y return). Both have compounded well over 10 years (VRTX: +425.4%, AIMD: -97.4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between AIMD and VRTX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.